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Malignant pleural effusionAbstract The glycoprotein YKL-40 is synthesized both by cancer cells and by tumor-associated
macrophages and plays a functional role in tumor progression. Consequently, high serum YKL-
40 levels have been associated with a poor prognosis in patients with several cancer types.
The aim of this study is to assess pleural effusion and serum concentrations of YKL-40 in
patients with different types of pleural effusions and to evaluate the diagnostic performance of
YKL-40 in detecting malignant pleural effusion.
Patients and methods: A prospective cohort study was carried out of 88 consecutive patients pre-
senting with pleural effusions. The patients were divided into four groups: 22 patients with tran-
sudative effusions, 24 patients with parapneumonic pleural effusion and 8 patients with
tuberculous pleural effusion and 34 patients with malignant pleural effusions. Blood and pleural
ﬂuid YKL-40 levels were measured using enzyme-linked immunosorbent assay.
Results: Both serum HE4 levels and pleural effusion YKL-40 levels were signiﬁcantly higher in
patients with malignant effusions than in patients with transudative or non-malignant exudative
effusions. A pleural ﬂuid YKL-40 cut-off value of 256 ng/mL was found to predict malignant pleu-
ral effusions with a diagnostic sensitivity of 85.3% and speciﬁcity of 90.7%.
Conclusion: The current study reports a ﬁnding of increased serum and pleural ﬂuid YKL-40
levels in patients with malignant pleural effusions compared to non-malignant effusions.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Pleural effusion is a commonly encountered presentation in
clinical practice, with a large number of possible causes,
including disease localized to the lung, primary or metastatic
pleural disease or a manifestation of systemic disease. The dif-
ferential diagnosis of a pleural effusion is wide, and pleuralrculosis.
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cause of a pleural effusion. It gives an indication about the
underlying pathophysiologic process and the need for further
investigations [1]. Light’s criteria is the most commonly used
parameter for the differentiation between exudative and tran-
sudative effusions [2] as it is a very robust test with a diagnostic
accuracy of 93–96% [3]. Malignant pleural effusions are a fre-
quent cause of exudative effusions, and their diagnosis often
poses a clinical challenge as pleural ﬂuid cytology is only posi-
tive in around 60% of cases on average [4,5]. More invasive
procedures such as thoracoscopy or thoracotomy may be
required to reach a diagnosis, but at the expense of higher mor-
bidity [6]. Numerous studies have been published analyzing the
potential utility of different tumor markers in pleural effusions
[7,8]. The chitinase-like protein YLK-40, also known as human
cartilage glycoprotein 39, is a glycoprotein produced in
association with various inﬂammatory and malignant pro-
cesses [9,10]. It is mainly secreted by macrophages, synovial
cells, chondrocytes, and neutrophils [11,10]. Although the
exact physiological function of YKL-40 protein is unknown,
the pattern of its expression suggests a role in inﬂammation
and tissue remodeling. Elevated serum YKL-40 levels have
been found in a wide range of inﬂammatory diseases including
asthma, cirrhosis, sarcoidosis, osteoarthritis, cardiovascular
disease, diabetes mellitus, rheumatoid arthritis, chronic
obstructive pulmonary disease, and inﬂammatory bowel dis-
ease. High serum concentration of YKL-40 has also been
found in various malignancies and seems to be a marker for
decreased survival [12–14]. YKL-40 is not speciﬁc for SCLC.
It is secreted by many different types of solid carcinomas
and also by non-malignant cells in tissues characterized by
inﬂammation, tissue degradation/remodeling or ongoing
ﬁbrogenesis. YKL-40 is produced by macrophages, neu-
trophils, malignant tumor cells, mesothelial cells and arthritic
chondrocytes [15], and has been found in the ﬁbrotic liver
[16]. Elevated serum YKL-40 levels are found in patients with
non-malignant diseases such as severe active rheumatoid
arthritis, severe bacterial infections and liver ﬁbrosis [17].
YKL-40 has been shown to be associated with lung injury
pathogenesis contributing to inﬂammation, remodeling and
cellular proliferation [18].
The aim of the current study was to assess pleural effusion
and serum concentrations of YKL-40 in patients with pleural
effusions of varying characteristics, and to evaluate the
diagnostic performance of YKL-40 in detecting malignant
pleural effusions.Patients and methods
A prospective cohort study was carried out of 88 consecutive
patients with pleural effusions seen in the pulmonary and
Oncology Departments of King Fahad Hospital Dammam.
The patients were subsequently divided into four groups
according to the type of effusion: transudative effusion
(TPE), parapneumonic pleural effusion (PPPE), tuberculous
pleural effusion (TBPE), and malignant pleural effusion
(MPE). Light’s criteria were calculated to differentiate exuda-
tive from transudative effusions. An effusion was classiﬁed as
malignant if tumor cells were found in the pleural ﬂuid or
pleural biopsy, or in a patient with disseminated malignancy
and no alternative explanation for an exudative effusion.Parapneumonic effusion was deﬁned as; the presence of pleural
effusion in patients with community-acquired pneumonia. We
used The American Thoracic Society criteria for deﬁning the
pneumonia [newly occurred respiratory symptoms, fever and
abnormal breath sounds, together with a new pulmonary inﬁl-
tration on chest X-ray, and consistent laboratory ﬁndings
(leukocytosis count and high serum CRP levels) and neu-
trophilic pleural effusion] [19]. Pleural ﬂuid samples were diag-
nosed as tuberculous effusion by pleural biopsy specimen
showing granulomas with caseiﬁcation necrosis, or pleural ﬂuid
positive on Ziehl-Nielsen stain or Lowenstein-Jensen culture,
or pleural ﬂuid consistent with clinical signs and symptoms of
tuberculosis together with lymphocyte predominance in pleural
effusion and good response to anti-tuberculosis treatment. The
study thereafter comprised twenty-two patients with transuda-
tive effusions, twenty-four patients with parapneumonic effu-
sions, eight patients with tuberculous effusion and thirty-four
patients with malignant effusions. Patients with transudative
effusions comprised 12 women and 10 men and were aged
(Mean ± SD) 60.2 ± 6.5 years. Patients with parapneumonic
effusions comprised 13 women and 11 men and were aged
(Mean ± SD) 59.8 ± 5.4 years. Patients with tuberculous effu-
sions comprised 3 women and 5 men and were aged
(Mean ± SD) 58.9 ± 8.9 years. Patients with malignant effu-
sions comprised of 18 males and 16 females and were aged;
(Mean ± SD) 63.5 ± 8.3 years (Table 1). Twenty-three
patients had lung cancer, 2 metastatic colon adenocarcinoma,
2 patients with non Hodgkin lymphoma, 2 patients with
metastatic gastric cancer and 5 patients with metastatic breast
cancer. Of the 23 patients with bronchial carcinoma,
histopathologically the cases comprised of 11 adenocarcinoma
(3 of them were well differentiated and 8 were moderately dif-
ferentiated), 12 cases of squamous cell carcinoma (3 of them
were moderately differentiated and the other 9 poorly differ-
entiated). Five out of the 11 distant metastatic cases originated
from breast cancer, and they were microscopically invasive
ductal carcinoma not otherwise speciﬁed (NOS), ranging from
grade II/III to grade III/IV. All patients included in this study
had unilateral pleural effusion except 2 patients of the tran-
sudative group with congestive heart failure. As per institution
guidelines, the study was approved by King Fahad Hospital
Ethics Committee. Informed consent was obtained from each
patient included in the study. Thoracocentesis was performed
under the aseptic technique, and pleural effusion and serum
samples were collected at the same time. The pleural ﬂuid was
collected in tubes containing EDTA for determination of the
cellular content, in plain tubes for determination of LDH, pro-
tein, albumin and YKL-40 levels. Paired serum samples were
analyzed for urea, creatinine, albumin, total protein, and
LDH levels. These parameters were measured using Siemens
Diagnostics (Marburg GmbH, Germany) (RxL Dimension
Clinical Chemistry analyzer) [20]. Pleural ﬂuid pH was mea-
sured using blood gas analyzer, GEM premier 3000 (instru-
mentation laboratory, USA). Sample for pleural ﬂuid pH was
collected anaerobically, kept on ice and analyzed immediately
within ﬁve minutes of collection. Pleural adenosine deaminase
(ADA) levels were also measured as UI/mL. For serum
YKL-40 analysis, the blood samples were centrifuged at
3000g for 10 min at 4 C. After the centrifugation, the serum
was removed and transferred into a clean test tube. All pleural
and serum samples were stored in a refrigerator at 80 C until
YKL-40 analysis and they were dissolved and stored for 24 h at
Table 1 Demographic data, clinical and biochemical criteria of the studied groups.
Parameters TPE PPPE TBPE MPE
N= 22 N= 24 N= 8 N= 34
Age 60.2 ± 6.5 59.8 ± 5.4 58.9 ± 8.9 63.5 ± 8.3
Sex M,10/F,12 M,11/F,13 M,5/F,3 M,18/F,16
BMI 20.8 ± 1.6 25.3 ± 3.4 25.3 ± 3.4 23.9 ± 3.4
BUN (mmol) 6.9 ± 4.7 4.9 ± 2.7 6.9 ± 4.7 6.19 ± 4.7
S. creatinine (lmol/L) 79 (42–45) 79.05(42–43) 79(42–39) 79(42–41)
S. protein (g/L) 62 ± 0.6 71 ± 0.9 71 ± 0.7 71 ± 0.5
S. albumin (g/L) 30 ± 0.34 36 ± 0.45 36 ± 0.58 37 ± 0.98
Blood WBCs · 103/mm3 5.5 ± 1.3 12.7 ± 3.2 11.2 ± 2.4 5.7 ± 1.9
Pl. WBCs 45.50(1–314) 980(345–4610) 950(339–3245) 1025(475–5346)
Pl. lymphocytic count 23.18 ± 10.95 17.72 ± 9.36 57.54 ± 8.6 64.3 ± 9.7
Pl. neutrophils count 23.2 ± 11.1 72.5 ± 13.05 25.76 ± 11.5 24.7 ± 9.4
Pl. PH 8 ± 0.26 7.21 ± 0.03 7.19 ± 0.04 7.22 ± 0.108
TPE: transudative pleural effusion, PPPE: parapneumonic pleural effusion, TBPE: tuberculous pleural effusion, MPE: malignant pleural
effusion, BMI: body mass index, BUN: blood urea nitrogen.
Evaluation of pleural ﬂuid YKL-40 4912–8 C before the study. YKL-40 protein concentrations were
determined in serum and pleural ﬂuids using a speciﬁc kit
(MICROVUE YKL-40 EIA Kit, Quidel, San Diego, USA)
by an enzyme-binding immunosorbent test (ELISA).
Standards, controls and the concentration of YKL-40 pre-
sented in the test specimens were measured by spectrophotome-
ter (PerkinElmer LAMBDA UV/Vis Spectrophotometer,
Massachusetts, USA) and the results are calculated from the
generated standard curve using linear regression analysis
according to the producer’s instructions [21].Statistical analysis
Comparison among the groups was conducted using analysis
of variance (ANOVA) test for normally distributed variables.
The non-parametric Mann–Whitney U test was used for vari-
ables with non-Gaussian distribution. For the choice of the
optimal cut-off, Receiver Operating Characteristic (ROC)
curves were constructed and the Youden index was calculated
[22]. The Youden index is deﬁned as follows: (sensitiv-
ity + speciﬁcity)  1. The best cut-off has the highest
Youden index. The commercial statistical software package
used was SPSS11.0 (SPSS, Inc., Chicago, IL, USA).Results
Demographic data, clinical and biochemical criteria of the
studied groups are illustrated in Table 1. Both serum and pleu-
ral ﬂuid levels YKL-40 were signiﬁcantly higher in the exuda-
tive pleural effusions group (i.e. parapneumonic effusion,
tuberculous effusion and malignant effusion) than the tran-
sudative group (p< 0.01). Median (range) values of serum
YKL-40 were 154(56–237.3) & 123(45–187) ng/mL and pleural
ﬂuid YKL-40 values were 194(85–265) & 141(78–187) ng/mL
in exudative and transudative groups respectively: (Fig. 1a).
In the exudative pleural effusion group pleural ﬂuid YKL-40
positively correlated with serum YKL-40 (r: 0.49 &
p< 0.001). Similarly serum YKL-40 positively correlated with
serum LDH (r: 0.383 & p= 0.002). Fig. 1b and d illustrates
serum and pleural effusion levels of YKL-40. Both serum
YKL-40 levels and effusion YKL-40 levels were signiﬁcantlyhigher in malignant effusions than in transudative or parap-
neumonic effusion, and tuberculous effusion (p< 0.05) while
YKL-40 pleural ﬂuid/serum ratio did not show signiﬁcant dif-
ference between the four groups. When malignant effusions
were classiﬁed according to the histopathological diagnosis,
there was no signiﬁcant difference between pleural and serum
YKL-40 levels in the different tumor types (p> 0.05). The
pleural effusion/serum ratio of LDH and albumin, pleural
effusion LDH level, YKL-40 serum level and YKL-40 pleural
effusion levels were evaluated as indicators for malignant effu-
sion using Receiver Operating Characteristic curve (ROC).
Effusion YKL-40 outperformed the other markers followed
by serum YKL-40, pleural ﬂuid LDH, Pleural ﬂuid/serum
LDH ratio then ﬁnally pleural ﬂuid/serum albumin ratio
(Fig. 1c). Pleural YKL-40/serum YKL-40 ratio >1.6 yielded
71% sensitivity, 73% speciﬁcity and likelihood ratio 2.8 for
diagnosing TBPE, with an area under the curve of 0.785
(95% CI: 0.711–0.890). The results of pleural ADA levels were
found to be high in pleural tuberculosis compared to other
pleural ﬂuids (p< 0.001) although we did not ﬁnd such a
correlation between serum and pleural YKL-40 and ADA
levels. The area under the curve (AUC) for ﬂuid YKL-40
was 0.886 (95% conﬁdence interval [CI] was 0.8–0.973). The
AUC for the serum YKL-40 was 0.798 (95% CI was 0.689–
0.907), while the AUC for the pleural ﬂuid LDH was 0.722
(95% CI was 0.617–0.827). The AUC for pleural ﬂuid LDH/
serum ratio was 0.615 (95% CI was 0.499–0.731). The AUC
for pleural ﬂuid lymphocyte count was 0.69 (95% CI was
0.544–0.836). The AUC for pleural ﬂuid neutrophil count
was 0.22 (and 95% CI was 0.123–0.317). Using the Youden
index, the best cut-off value for pleural ﬂuid YKL-40 to pre-
dict malignant effusions was 256 ng/mL. This cut-off value
had a diagnostic sensitivity of 85.3% and speciﬁcity of
90.7%. The best cut-off value for pleural ﬂuid YKL-40 to dif-
ferentiate between exudative and transudative effusions was
212 ng/mL. This cut-off value had a diagnostic sensitivity of
74.3% and speciﬁcity of 75.7% (see Tables 2 and 3).
Discussion
The diagnosis of malignancy in pleural effusion is a challeng-
ing clinical problem. Several studies have been published
Figure 1 HE4 levels in the different groups and YKL-40 AUC under a ROC curve. Boxplots (a, b and d) illustrate YKL-40 values in
serum, and pleural effusion in patients with transudative effusion (TPE), parapneumonic pleural effusion (PPPE), tuberculous pleural
effusion (TBPE) and malignant pleural effusions (MPE). The boxplots represent the interquartile range from the 25th to the 75th
percentiles. The whiskers below and above the boxes represent the minimum and maximum values. The line across each box represents the
median value. (c) ROC curves were constructed by plotting the sensitivity versus 1-speciﬁcity at different cut-off values for each analyte.
EPE: Exudative pleural effusion, P: Pleural, S: Serum.
Table 2 Pleural, serum YKL-40 and pleural/serum ratio
values in the transudative and exudative effusion patients.
Parameters TPE EPE p value
(n= 22) (n= 66)
Pleural YKL-40 ng/mL 141(78–187) 194(85–265) <0.001
Serum YKL-40 ng/mL 123(45–187) 154(56.7–237.3) <0.05
PL/S YKL-40 ratio 1.05(0.8–5.5) 2.16(1.01–6.02) <0.001
TPE: transudative pleural effusion, EPE: exudative pleural effusion,
PL/S: pleural/serum.
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nant pleural effusions [23], however, none of these markers
gained consensus as a highly sensitive marker for neoplastic
effusions due to varied sensitivity and speciﬁcity [24] or speci-
ﬁcity for certain neoplasms (e.g. mesothelioma) [25]. The
search therefore continues for a marker or combination of
markers that will increase the ability to diagnose malignancyin a pleural effusion, and to select those patients who would
beneﬁt from more extensive invasive investigation when the
pleural ﬂuid cytology is negative. Proposed cut-off values for
pleural tumor markers have varied in several studies; however
some authors have suggested that cut-off points for a tumor
marker that allows 100% speciﬁcity are necessary to sub-
stantiate a diagnosis of a malignant pleural effusion.
Adopting such high cut-off points has resulted in the sensitiv-
ity of single tumor markers to predict malignancy to be as low
as 17–30% [8]. The current study found a signiﬁcantly higher
level of YKL-40 in serum of patients with exudative effusion
than those with transudative ones. The best cut-off value for
pleural ﬂuid YKL-40 to differentiate between exudative and
transudative effusions was 212 ng/mL. This cut-off value had
a diagnostic sensitivity of 74.3% and speciﬁcity of 75.7%.
Most importantly, a marked signiﬁcant increase was found
in serum of patients with neoplastic pleural effusions than
those with non-malignant exudative effusions and transudative
effusions. This ﬁnding was also mirrored by an increased
Table 3 Pleural, serum, and pleural/serum ratio values of some biochemical parameters evaluated in the study.
Parameters TPE PPPE TBPE MPE
(n= 22) (n= 24) (n= 8) (n= 34)
Protein(g/L)
Pleural 22.7 ± 2.7 39 ± 2.4 43 ± 1.9 41.6 ± 6.4
Serum 62 ± 5.9 70.2 ± 5.7 70.3 ± 5.9 70.1 ± 5.2
PL/S ratio 1.9 ± 0.21 1.8 ± 0.17 1.8 ± 0.21 1.7 ± 0.23
Albumin(g/L)
Pleural 16 ± 4.1 32.29 ± 1.5 28.11 ± 1.8 29 ± 4.9
Serum 30 ± 4.8 36 ± 3.5 36.2 ± 1.4 37.4 ± 3.6
PL/S ratio 0.52 0.84 ± 0.09 0.81 ± 0.08 0.80 ± 0.09
LDH(U/L)
Pleural 59.68 ± 19.9 755 ± 274.3 721 ± 187.46 843.1 ± 501.3
Serum 151 ± 47.9 209.2 ± 86.1 301.8 ± 84 332.8 ± 214
PL/S ratio 0.42 ± 0.14 4.16 ± 2.4 5.12 ± 3.5 3.03 ± 1.19
Pleural ADA(U/mL) 12(1–25) 16(1–39) 48(23–100) 14(1–37)
YKL-40 (ng/mL)
Pleural 141(78–187) 154(55–224) 182(65–235) 255(135–335)
Serum 123(45–187) 149(59–200) 109(52–200) 205(59–312)
PL/S ratio 1.05(0.8–5.5) 1.09(0.81–5.44) 4.11(1.3–6.7) 1.28(0.91–5.92)
TPE: transudative pleural effusion, PPPE: parapneumonic pleural effusion, TBPE: tuberculous pleural effusion, MPE: malignant pleural
effusion, PL/S: pleural/serum, ADA: adenosine deaminase, LDH: lactic dehydrogenase.
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compared to those with transudative or non-malignant exuda-
tive effusions. This ﬁnding may be explained by increased local
secretion of YKL-40 that is produced by the neoplastic tissues
with subsequent overload to the systemic circulation resulting
in increased serum YKL-40. The current study did not ﬁnd a
signiﬁcant difference in pleural ﬂuid YKL-40 between primary
pulmonary neoplasm and secondary metastatic pleural effu-
sions. This increase in pleural ﬂuid YKL-40 may be due to
increased secretion by the malignant cells in cases of primary
pulmonary neoplasm or local irritation of respiratory epithe-
lial cells with subsequent increase in YKL-40 local production
in secondary metastatic pleural effusions. Furthermore the
observed lack of correlation between serum or pleural ﬂuid
YKL-40 and the histopathological type of the tumor may be
explained by the fact that all patients with malignant pleural
effusion were advance metastatic stage IV patients according
to TNM staging system. The metastasis may have caused
increased production of YKL-40 either through local irritation
or cellular destruction irrespective of the histopathological
tumor origin.
The biologic functions of YKL-40 in cancer cells are
unknown, and very few studies have evaluated the functional
role of YKL-40 expression in cancer cells. It has been sug-
gested that YKL-40 plays a role in the proliferation and differ-
entiation of malignant cells, protects the cells from undergoing
apoptosis, YKL-40 is a relatively new biomarker of inﬂamma-
tion and it has been further investigated in several pathologic
conditions [26]. Funkhouser et al. [27] reported that the levels
of YKL-40 in the lung and serum are increased in asthma and
other inﬂammatory and remodeling disorders correlating with
disease severity. Kim et al. [28] studied YKL-40 levels in differ-
ent lung diseases and pleural effusions, they found that the
results of serum YKL-40 were the highest in tuberculosis com-
pared with other pleural effusions including parapneumonic,and cardiogenic effusions. Bouzas et al. [29] demonstrated a
signiﬁcant relation between chitotriosidase and ADA activi-
ties, although we did not ﬁnd such a correlation between serum
and pleural YKL-40 and ADA levels. Contrary to our results,
Kim et al. [28] reported that serum YKL-40 level of the
patients with pleural tuberculous was higher than that of the
patients with effusions due to malignant or cardiac causes.
The current study showed a positive correlation between pleu-
ral ﬂuid YKL-40 and LDH point more to the possible value of
increased YKL-40 level in malignant effusion. The increased
levels of both markers (LDH and YKL-40) in pleural ﬂuid
may be secondary to increased local production either through
increased cellular destruction, local invasion or local tissue irri-
tation. The current study had shown a signiﬁcant increase in
pleural ﬂuid lymphocytic count in patients with malignant
pleural effusion, and a good AUC for pleural lymphocytic
count. However increased pleural ﬂuid lymphocytic count
may be found in other disease states (e.g. Tuberculosis, pul-
monary embolism) [30]. Pleural YKL-40/serum YKL-40 ratio
>1.6 yielded 71% sensitivity, 73% speciﬁcity and likelihood
ratio 2.8 for diagnosing TBPE, with an area under the curve
of 0.785 (95% CI: 0.711–0.890). The use of pleural ﬂuid/serum
ratio to enhance the diagnostic sensitivity of tuberculous effu-
sion was evaluated by Kayhan et al. [31] who found, Pleural
YKL-40/serum YKL-40 ratio >1.5 yielded 75% sensitivity,
72% speciﬁcity and likelihood ratio 2.6 for diagnosing
TBPE, with an area under the curve of 0.825 (95% CI:
0.710–0.940). The current study did not ﬁnd a signiﬁcant dif-
ference in pleural ﬂuid/serum YKL-40 ratio between the tran-
sudative and exudative effusions. The use of pleural ﬂuid/
serum ratio to enhance the diagnostic sensitivity of tumor
markers was evaluated by Trape´ et al. [32] who classiﬁed
tumor markers into two categories: released/secreted by nor-
mal pleura (e.g. CA-125 and cytokeratin) and non released/
non-secreted tumor markers (e.g. CEA and CA-19.9) by
494 A. Attia et al.normal pleura. Trape´ et al. showed clearly that the ﬂuid/serum
ratio was only useful for non-secreted tumor markers while for
secreted tumor markers (i.e. those that may be secreted by nor-
mal respiratory epithelium) the ratio did not improve their
sensitivity and speciﬁcity. As YKL-40 has been previously
shown to be expressed by normal respiratory epithelium, it
may be considered as a secreted/released tumor marker and
it would not be surprising that pleural/ﬂuid serum YKL-40
ratio did not enhance its diagnostic sensitivity and speciﬁcity
due to possible concomitant increase in serum and pleural ﬂuid
YKL-40 with the net result of a normal or reduced ratio of
pleural ﬂuid/serum YKL-40 ratio. An important ﬁnding of
the current study is the superior performance of pleural effu-
sion YKL-40 levels in detecting malignant pleural effusions
with a value of 256 ng/mL as the best cut-off value to suggest
a malignant pleural effusion with a diagnostic sensitivity of
85.3% and speciﬁcity of 90.7%. Even when the cut-off point
was increased to 286 ng/mL to achieve 100% speciﬁcity, the
marker still predicted malignancy with a sensitivity of 45%.
This result favors comparably with other similar studies
examining the utility of single tumor markers where the
achieved sensitivity was very low when a 100% speciﬁcity
cut-off was chosen. This is the ﬁrst study to examine the role
of YKL-40 in the diagnosis of malignancy in pleural effusions,
and it was limited by the relatively small number of subjects,
and therefore the utility of this marker will have little clinical
beneﬁt currently.
Conclusion
However this novel ﬁnding of increased pleural ﬂuid YKL-40
levels in malignant pleural effusions compared to either tran-
sudative or non-malignant exudative effusions will add to
our scientiﬁc knowledge, and set the stage for larger studies
of this marker in pleural effusions, or the inclusion of this mar-
ker in combination with other panels to strengthen the
diagnostic performance of tumor markers in detecting malig-
nant pleural effusions.Conﬂict of interest
The authors declare no conﬂict of interests.
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